11 results on '"Cursano, Giulia"'
Search Results
2. ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
- Author
-
Venetis, Konstantinos, Pepe, Francesco, Pescia, Carlo, Cursano, Giulia, Criscitiello, Carmen, Frascarelli, Chiara, Mane, Eltjona, Russo, Gianluca, Taurelli Salimbeni, Beatrice, Troncone, Giancarlo, Guerini Rocco, Elena, Curigliano, Giuseppe, Fusco, Nicola, and Malapelle, Umberto
- Published
- 2023
- Full Text
- View/download PDF
3. Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey
- Author
-
Fusco, Nicola, Ivanova, Mariia, Frascarelli, Chiara, Criscitiello, Carmen, Cerbelli, Bruna, Pignataro, Maria Gemma, Pernazza, Angelina, Sajjadi, Elham, Venetis, Konstantinos, Cursano, Giulia, Pagni, Fabio, Di Bella, Camillo, Accardo, Marina, Amato, Michelina, Amico, Paolo, Bartoli, Caterina, Bogina, Giuseppe, Bortesi, Laura, Boldorini, Renzo, Bruno, Sara, Cabibi, Daniela, Caruana, Pietro, Dainese, Emanuele, De Camilli, Elisa, Dell’Anna, Vladimiro, Duda, Loren, Emmanuele, Carmela, Fanelli, Giuseppe Nicolò, Fernandes, Bethania, Ferrara, Gerardo, Gnetti, Letizia, Gurrera, Alessandra, Leone, Giorgia, Lucci, Raffaella, Mancini, Cristina, Marangi, Grazia, Mastropasqua, Mauro G., Nibid, Lorenzo, Orrù, Sandra, Pastena, Maria, Peresi, Monica, Perracchio, Letizia, Santoro, Angela, Vezzosi, Vania, Zambelli, Claudia, Zuccalà, Valeria, Rizzo, Antonio, Costarelli, Leopoldo, Pietribiasi, Francesca, Santinelli, Alfredo, Scatena, Cristian, Curigliano, Giuseppe, Guerini-Rocco, Elena, Martini, Maurizio, Graziano, Paolo, Castellano, Isabella, and d'Amati, Giulia
- Published
- 2023
- Full Text
- View/download PDF
4. Liquid biopsy: Cell-free DNA based analysis in breast cancer
- Author
-
Venetis, Konstantinos, Cursano, Giulia, Pescia, Carlo, D'Ercole, Marianna, Porta, Francesca Maria, Blanco, Marta Cruz, Frascarelli, Chiara, Ivanova, Mariia, Guerini Rocco, Elena, and Fusco, Nicola
- Published
- 2023
- Full Text
- View/download PDF
5. The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy.
- Author
-
Venetis, Konstantinos, Pescia, Carlo, Cursano, Giulia, Frascarelli, Chiara, Mane, Eltjona, De Camilli, Elisa, Munzone, Elisabetta, Dellapasqua, Silvia, Criscitiello, Carmen, Curigliano, Giuseppe, Guerini Rocco, Elena, and Fusco, Nicola
- Subjects
CANCER diagnosis ,PROGNOSIS ,BREAST cancer - Abstract
Multigene prognostic genomic assays have become indispensable in managing early breast cancer (EBC), offering crucial information for risk stratification and guiding adjuvant treatment strategies in conjunction with traditional clinicopathological parameters. The American Society of Clinical Oncology (ASCO) guidelines endorse these assays, though some clinical contexts still lack definitive recommendations. The dynamic landscape of EBC management demands further refinement and optimization of genomic assays to streamline their incorporation into clinical practice. The breast cancer community is poised at the brink of transformative advances in enhancing the clinical utility of genomic assays, aiming to significantly improve the precision and effectiveness of both diagnosis and treatment for women with EBC. This article methodically examines the testing methodologies, clinical validity and utility, costs, diagnostic frameworks, and methodologies of the established genomic tests, including the Oncotype Dx Breast Recurrence Score
® , MammaPrint, Prosigna® , EndoPredict® , and Breast Cancer Index (BCI). Among these tests, Prosigna and EndoPredict® have at present been validated only on a prognostic level, while Oncotype Dx, MammaPrint, and BCI hold both a prognostic and predictive role. Oncologists and pathologists engaged in the management of EBC will find in this review a thorough comparison of available genomic assays, as well as strategies to optimize the utilization of the information derived from them. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
6. Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence.
- Author
-
Ivanova, Mariia, Pescia, Carlo, Trapani, Dario, Venetis, Konstantinos, Frascarelli, Chiara, Mane, Eltjona, Cursano, Giulia, Sajjadi, Elham, Scatena, Cristian, Cerbelli, Bruna, d'Amati, Giulia, Porta, Francesca Maria, Guerini-Rocco, Elena, Criscitiello, Carmen, Curigliano, Giuseppe, and Fusco, Nicola
- Subjects
BREAST tumor risk factors ,RISK assessment ,MEDICAL protocols ,CANCER relapse ,ARTIFICIAL intelligence ,EARLY detection of cancer ,CYTOCHEMISTRY ,TUMOR markers ,DECISION making in clinical medicine ,IMMUNOHISTOCHEMISTRY ,PATIENT-centered care ,DEEP learning ,ARTIFICIAL neural networks ,MACHINE learning ,ONCOLOGISTS ,INDIVIDUALIZED medicine ,MOLECULAR pathology ,HEALTH care teams ,ALGORITHMS ,DISEASE risk factors - Abstract
Simple Summary: Risk assessment in early breast cancer is critical for clinical decisions, but defining risk categories poses a significant challenge. The integration of conventional histopathology and biomarkers with artificial intelligence (AI) techniques, including machine learning and deep learning, has the potential to offer more precise information. AI applications extend beyond detection to histological subtyping, grading, and molecular feature identification. The successful integration of AI into clinical practice requires collaboration between histopathologists, molecular pathologists, computational pathologists, and oncologists to optimize patient outcomes. Effective risk assessment in early breast cancer is essential for informed clinical decision-making, yet consensus on defining risk categories remains challenging. This paper explores evolving approaches in risk stratification, encompassing histopathological, immunohistochemical, and molecular biomarkers alongside cutting-edge artificial intelligence (AI) techniques. Leveraging machine learning, deep learning, and convolutional neural networks, AI is reshaping predictive algorithms for recurrence risk, thereby revolutionizing diagnostic accuracy and treatment planning. Beyond detection, AI applications extend to histological subtyping, grading, lymph node assessment, and molecular feature identification, fostering personalized therapy decisions. With rising cancer rates, it is crucial to implement AI to accelerate breakthroughs in clinical practice, benefiting both patients and healthcare providers. However, it is important to recognize that while AI offers powerful automation and analysis tools, it lacks the nuanced understanding, clinical context, and ethical considerations inherent to human pathologists in patient care. Hence, the successful integration of AI into clinical practice demands collaborative efforts between medical experts and computational pathologists to optimize patient outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.
- Author
-
Ivanova, Mariia, Porta, Francesca Maria, D'Ercole, Marianna, Pescia, Carlo, Sajjadi, Elham, Cursano, Giulia, De Camilli, Elisa, Pala, Oriana, Mazzarol, Giovanni, Venetis, Konstantinos, Guerini-Rocco, Elena, Curigliano, Giuseppe, Viale, Giuseppe, and Fusco, Nicola
- Abstract
Since the release of the DESTINY-Breast04 (DB-04) trial findings in June 2022, the field of pathology has seen a renaissance of HER2 as a predictive biomarker in breast cancer. The trial focused on patients with metastatic breast cancer who were classified as "HER2-low," i.e., those with immunohistochemistry (IHC) HER2 1 + or 2 + and negative in situ hybridization (ISH) results. The study revealed that treating these patients with trastuzumab deruxtecan (T-DXd) instead of the oncologist's chosen chemotherapy led to outstanding improvements in survival. This has challenged the existing binary HER2 pathological classification system, which categorized tumors as either positive (overexpression/amplification) or negative, as per the ASCO/CAP 2018 guideline reaffirmed by ASCO/CAP 2023 guideline update. Given that DB-04 excluded patients with HER2 IHC score 0 status, the results of the ongoing DB-06 trial may shed further light on the potential benefits of T-DXd therapy for these patients. Roughly half of all breast cancers are estimated to belong to the HER2-low category, which does not represent a distinct or specific subtype of cancer. Instead, it encompasses a diverse group of tumors that exhibit clinical, morphological, immunohistochemical, and molecular variations. However, HER2-low offers a distinctive biomarker status that identifies a specific therapeutic regimen (i.e., T-DXd) linked to a favorable prognosis in breast cancer. This unique association emphasizes the importance of accurately identifying these tumors. Differentiating between a HER2 IHC score 0 and score 1 + has not been clinically significant until now. To ensure accurate classification and avoid misdiagnosis, it is necessary to adopt standardized procedures, guidelines, and specialized training for pathologists in interpreting HER2 expression in the lower spectrum. Additionally, the utilization of artificial intelligence holds promise in supporting this endeavor. Here, we address the current state of the art and unresolved issues in assessing HER2-low status, with a particular emphasis on the score 0. We explore the dilemma surrounding the exclusion of HER2-zero patients from potentially beneficial therapy based on traditional HER2 testing. Additionally, we examine the clinical context, considering that DB-04 primarily involved heavily pretreated late-stage metastatic breast cancers. We also delve into emerging evidence suggesting that extrapolating HER2-low status from the original diagnosis may lead to misleading results. Finally, we provide recommendations for conducting high-quality testing and propose a standardized pathology report in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing.
- Author
-
Ranghiero, Alberto, Frascarelli, Chiara, Cursano, Giulia, Pescia, Carlo, Ivanova, Mariia, Vacirca, Davide, Rappa, Alessandra, Taormina, Sergio Vincenzo, Barberis, Massimo, Fusco, Nicola, Rocco, Elena Guerini, and Venetis, Konstantinos
- Subjects
CIRCULATING tumor DNA ,METASTATIC breast cancer ,TISSUE analysis ,DISEASE progression ,BREAST cancer - Abstract
Breast cancer biomarker profiling predominantly relies on tissue testing (surgical and/or biopsy samples). However, the field of liquid biopsy, particularly the analysis of circulating tumour DNA (ctDNA), has witnessed remarkable progress and continues to evolve rapidly. The incorporation of ctDNA‐based testing into clinical practice is creating new opportunities for patients with metastatic breast cancer (MBC). ctDNA offers advantages over conventional tissue analyses, as it reflects tumour heterogeneity and enables multiple serial biopsies in a minimally invasive manner. Thus, it serves as a valuable complement to standard tumour tissues and, in certain instances, may even present a potential alternative approach. In the context of MBC, ctDNA testing proves highly informative in the detection of disease progression, monitoring treatment response, assessing actionable biomarkers, and identifying mechanisms of resistance. Nevertheless, ctDNA does exhibit inherent limitations, including its generally low abundance, necessitating timely blood samplings and rigorous management of the pre‐analytical phase. The development of highly sensitive assays and robust bioinformatic tools has paved the way for reliable ctDNA analyses. The time has now come to establish how ctDNA and tissue analyses can be effectively integrated into the diagnostic workflow of MBC to provide patients with the most comprehensive and accurate profiling. In this manuscript, we comprehensively analyse the current methodologies employed in ctDNA analysis and explore the potential benefits arising from the integration of tissue and ctDNA testing for patients diagnosed with MBC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods.
- Author
-
Porta, Francesca Maria, Sajjadi, Elham, Venetis, Konstantinos, Frascarelli, Chiara, Cursano, Giulia, Guerini-Rocco, Elena, Fusco, Nicola, and Ivanova, Mariia
- Subjects
TRIPLE-negative breast cancer ,HARBOR maintenance & repair ,TEST methods ,BIOMARKERS ,PROGNOSIS - Abstract
Triple-negative breast cancer (TNBC) poses a significant challenge in terms of prognosis and disease recurrence. The limited treatment options and the development of resistance to chemotherapy make it particularly difficult to manage these patients. However, recent research has been shifting its focus towards biomarker-based approaches for TNBC, with a particular emphasis on the tumor immune landscape. Immune biomarkers in TNBC are now a subject of great interest due to the presence of tumor-infiltrating lymphocytes (TILs) in these tumors. This characteristic often coincides with the presence of PD-L1 expression on both neoplastic cells and immune cells within the tumor microenvironment. Furthermore, a subset of TNBC harbor mismatch repair deficient (dMMR) TNBC, which is frequently accompanied by microsatellite instability (MSI). All of these immune biomarkers hold actionable potential for guiding patient selection in immunotherapy. To fully capitalize on these opportunities, the identification of additional or complementary biomarkers and the implementation of highly customized testing strategies are of paramount importance in TNBC. In this regard, this article aims to provide an overview of the current state of the art in immune-related biomarkers for TNBC. Specifically, it focuses on the various testing methodologies available and sheds light on the immediate future perspectives for patient selection. By delving into the advancements made in understanding the immune landscape of TNBC, this study aims to contribute to the growing body of knowledge in the field. The ultimate goal is to pave the way for the development of more personalized testing strategies, ultimately improving outcomes for TNBC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management.
- Author
-
Ivanova, Mariia, Porta, Francesca Maria, Giugliano, Federica, Frascarelli, Chiara, Sajjadi, Elham, Venetis, Konstantinos, Cursano, Giulia, Mazzarol, Giovanni, Guerini-Rocco, Elena, Curigliano, Giuseppe, Criscitiello, Carmen, and Fusco, Nicola
- Subjects
METASTATIC breast cancer ,BREAST ,BRAIN metastasis ,COLONIZATION (Ecology) ,BLOOD-brain barrier ,BREAST cancer - Abstract
Breast cancer is the most frequently diagnosed malignancy worldwide and the leading cause of cancer-related death among women. Brain metastases are a primary contributor to mortality, as they often go undetected until late stages due to their dormant nature. Moreover, the clinical management of brain metastases is complicated by the relevant issue of blood-brain barrier penetration. The molecular pathways involved in the formation, progression, and colonization of primary breast tumors and subsequent brain metastases are diverse, posing significant hurdles due to the heterogeneous nature of breast cancer subtypes. Despite advancements in primary breast cancer treatments, the prognosis for patients with brain metastases remains poor. In this review, we aim to highlight the biological mechanisms of breast cancer brain metastases by evaluating multi-step genetic pathways and to discuss currently available and emerging treatment strategies to propose a prospective overview of the management of this complex disease. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. 2613: Preoperative single-fraction RT for earlystage BC: preliminary results from CRYSTAL phase I/II study.
- Author
-
Zerella, Maria Alessia, Zaffaroni, Mattia, Mazzola, Giovanni Carlo, Ronci, Giuseppe, Dicuonzo, Samantha, Rojas, Damaris Patricia, Morra, Anna, Gerardi, Marianna Alessandra, Fodor, Cristiana, Rondi, Elena, Vigorito, Sabrina, Penco, Silvia, Sargenti, Manuela, Vicini, Elisa, Galimberti, Viviana Enrica, Gandini, Sara, Cursano, Giulia, De Camilli, Elisa, Cattani, Federica, and Veronesi, Paolo
- Subjects
- *
CRYSTALS - Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.